Sumatriptan nasal spray (20 mg/dose) in the acute treatment of XXXX .

@entity1 @entity2686 @entity158 @entity9251
Subcutaneous injection of @entity9251 is an effective treatment for attacks of @entity2686 with a short onset of action. This open, randomized study evaluates whether sumatriptan nasal spray at its highest commercially available dose (20 mg/dose) is equally effective. In 26 @entity1 , four consecutive attacks were treated alternately with nasal spray and subcutaneous injection. Treatment was given within 5 min of onset of @entity158 , and the time interval for the start and completeness of @entity158 relief, provided these occurred within 15 min of administration, were recorded by the @entity1 . After completion of the study, the @entity1 were also asked to indicate which treatment they preferred, based on efficacy, side effects, and handling of the preparation. Forty-nine of the 52 treatments with injection resulted in complete relief of @entity158 within 15 min, with a mean of 9.6 min. The remaining three attacks were reduced by a mean of 86.7% at 15 min. Only 7 of the 52 treatments with nasal spray in the nostril ipsilateral to @entity158 resulted in complete relief within this time period, with a mean of 13.0 min. In 18 of these treatments @entity158 was reduced by a mean of 42.2% at 15 min, whereas no effect on @entity158 was obtained at this time in the remaining 27 treatments. The effect was almost identical when the nasal spray was administered in the nostril on the non-painful side. As an overall judgement, only 2 of the 26 @entity1 preferred nasal spray to injection. We conclude that sumatriptan nasal spray 20 mg/dose is less effective than subcutaneous injection in relieving @entity158 in the great majority of @entity2686 sufferers.
